Filtered By:
Source: Circulation
Condition: Heart Attack
This page shows you your search results in order of date.
Order by Relevance | Date
Total 272 results found since Jan 2013.
Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial
CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT02100722.PMID:37602376 | DOI:10.1161/CIRCULATIONAHA.123.065770
Source: Circulation - August 21, 2023 Category: Cardiology Authors: Frederik M Zimmermann Victoria Y Ding Nico H J Pijls Zsolt Piroth Albert H M van Straten Laszlo Szekely Giedrius Davidavicius Gintaras Kalinauskas Samer Mansour Rajesh Kharbanda Nikolaos Östlund-Papadogeorgos Adel Aminian Keith G Oldroyd Nawwar Al-Attar Source Type: research
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial
CONCLUSIONS: Frailty status was a marker of high cardiovascular risk. Patients with frailty benefit similarly to other patients from intensive blood pressure control without an increased risk of serious adverse events.PMID:37401465 | DOI:10.1161/CIRCULATIONAHA.123.064003
Source: Circulation - July 4, 2023 Category: Cardiology Authors: Zhiyan Wang Xin Du Chang Hua Wenjie Li Hao Zhang Xinru Liu Yufeng Wang Chao Jiang Jiakun Guo Qiang Lv Craig S Anderson Jianzeng Dong Changsheng Ma Source Type: research
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04508023.PMID:37154020 | DOI:10.1161/CIRCULATIONAHA.123.063901
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Gregory Piazza Alex C Spyropoulos Judith Hsia Mark Goldin William J Towner Alan S Go Todd M Bull Stephen Weng Concetta Lipardi Elliot S Barnathan Marc P Bonaca PREVENT-HD Investigators Source Type: research
Sex Differences in Cardiac Troponin Trajectories Over the Life Course
CONCLUSIONS: Trajectories of cardiac troponin differ between women and men in the general population, with differing associations to conventional risk factors and cardiovascular outcomes. Our findings highlight the importance of a sex-specific approach when serial cardiac troponin testing is applied for cardiovascular risk prediction.PMID:37114498 | DOI:10.1161/CIRCULATIONAHA.123.064386
Source: Circulation - April 28, 2023 Category: Cardiology Authors: Marie de Bakker Atul Anand Martin Shipley Takeshi Fujisawa Anoop S V Shah Isabella Kardys Eric Boersma Eric J Brunner Nicholas L Mills Dorien M Kimenai Source Type: research
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research
